<p>Norden Group LLC 在最近向證券交易委員會（SEC）提交的 13F 表格中表示，在第三季度將其在賽默飛世爾（Thermo Fisher Scientific Inc.，NYSE:TMO - 免費報告）的持股減少了 76.3%。該機構投資者在此期間出售了 4,226 股後，持有該醫療研究公司 1,315 股股票。Norden Group LLC 在賽默飛世爾的持股在最近一個季度末的價值為 638,000 美元。</p>
<ul>
<li>行業輪動：2026 年的 2 個聰明資金動向</li>
</ul>
<p>其他對沖基金最近也調整了對該公司的持股。Heathbridge Capital Management Ltd. 在第三季度新購入了約 230,000 美元的賽默飛世爾股份。Triangle Securities Wealth Management 在第三季度將其在賽默飛世爾的持股增加了 5.2%。Triangle Securities Wealth Management 目前持有 2,805 股該醫療研究公司的股票，價值 1,360,000 美元，此前在上個季度又購買了 139 股。Founders Financial Securities LLC 在第三季度將其在賽默飛世爾的持股增加了 11.1%。Founders Financial Securities LLC 目前持有 2,367 股該醫療研究公司的股票，價值 1,148,000 美元，此前在上個季度又購買了 237 股。Cape ANN Savings Bank 在第三季度新購入了約 210,000 美元的賽默飛世爾股份。最後，Value Partners Investments Inc. 在第三季度將其在賽默飛世爾的持股增加了 1.6%。Value Partners Investments Inc. 目前持有 10,440 股該醫療研究公司的股票，價值 5,061,000 美元，此前在上個季度又購買了 160 股。目前，89.23% 的股票由機構投資者和對沖基金持有。</p>
<h2>分析師設定新目標價</h2>
<p>幾位股票研究分析師最近對該公司發表了看法。花旗集團將賽默飛世爾的評級從 “中性” 上調至 “買入”，並在 12 月 11 日的研究報告中將其目標價從 580.00 美元上調至 660.00 美元。KeyCorp 將賽默飛世爾的評級從 “行業權重” 上調至 “超配”，並在 12 月 7 日的研究報告中設定了 750.00 美元的目標價。滙豐全球研究在 12 月 1 日的報告中將賽默飛世爾的評級從 “持有” 上調至 “強力買入”。瑞銀集團在 10 月 23 日的報告中將賽默飛世爾的目標價從 500.00 美元上調至 590.00 美元，並給予該股票 “中性” 評級。最後，TD Cowen 在 10 月 23 日的報告中將賽默飛世爾的目標價從 612.00 美元上調至 654.00 美元，並給予公司 “買入” 評級。一位分析師給予該股票 “強力買入” 評級，二十位給予 “買入” 評級，三位給予 “持有” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 616.60 美元。</p>
<ul>
<li>機構熱愛這 3 家公司，你也應該嗎？</li>
</ul>
<p><strong>查看我們關於賽默飛世爾的最新報告</strong></p>
<h2>賽默飛世爾的內部交易</h2>
<p>在相關消息中，副總裁 Lisa P. Britt 於 11 月 7 日星期五出售了 10,225 股公司的股票，交易平均價格為 571.62 美元，總價值為 5,844,814.50 美元。出售完成後，該副總裁持有 14,145 股公司的股票，價值約為 8,085,564.90 美元。此次交易使其持股減少了 41.96%。該出售在 SEC 的備案中披露，您可以通過此鏈接訪問。此外，執行副總裁 Michael D. Shafer 於 11 月 25 日星期二出售了 10,725 股公司的股票，交易平均價格為 600.00 美元，總交易額為 6,435,000.00 美元。交易完成後，該執行副總裁直接持有 18,731 股公司的股票，價值約為 11,238,600 美元。此次交易使其持股減少了 36.41%。該出售的披露信息可在 SEC 的備案中找到。在過去的九十天裏，內部人士已出售 149,271 股公司股票，價值 86,507,282 美元。公司內部人士持有 0.33% 的公司股票。</p>
<h2>賽默飛世爾股票上漲 0.3%</h2>
<ul>
<li>這 3 只股票正在利用回購來傳達市場信心</li>
</ul>
<p>NYSE:TMO 週五開盤價為 580.65 美元。該股票的市值為 2181.6 億美元，市盈率為 33.54，市盈增長比率為 4.11，貝塔係數為 0.90。賽默飛世爾的 52 周低點為 385.46 美元，52 周高點為 610.97 美元。該公司的債務與股本比率為 0.62，流動比率為 1.50，速動比率為 1.11。該股票的 50 日移動平均線為 573.94 美元，200 日移動平均線為 502.88 美元。</p>
<p>賽默飛世爾（NYSE:TMO - 獲取免費報告）最近於 10 月 22 日星期三發佈了季度財報。該醫療研究公司報告該季度每股收益為 5.79 美元，超出市場共識預期的 5.50 美元，超出幅度為 0.29 美元。該公司在該季度的收入為 111.2 億美元，而分析師預期為 109 億美元。賽默飛世爾的淨利潤率為 15.02%，股本回報率為 16.97%。該公司的季度收入較去年同期增長了 4.9%。去年同期，該公司每股收益為 5.28 美元。賽默飛世爾已將其 2025 財年的指導目標設定為每股收益 22.600-22.860 美元。整體來看，股票研究分析師預測賽默飛世爾在當前財年將發佈每股收益 23.28 美元。</p>
<h2>賽默飛世爾分紅公告</h2>
<p>該公司最近還披露了季度股息，將於 1 月 15 日（星期四）支付。12 月 15 日（星期一）登記的投資者將獲得每股 0.43 美元的股息。這相當於每年 1.72 美元的股息和 0.3% 的股息收益率。除息日期為 12 月 15 日（星期一）。賽默飛世爾的股息支付比率（DPR）目前為 9.94%。</p>
<p>賽默飛世爾宣佈，其董事會於 11 月 6 日（星期四）啓動了一項股票回購計劃，允許公司回購 50 億美元的股份。該回購授權允許這家醫療研究公司通過公開市場購買最多 2.4% 的股份。股票回購計劃通常表明公司的管理層認為其股票被低估。</p>
<h2>賽默飛世爾簡介</h2>
<p>（免費報告）</p>
<p>賽默飛世爾（NYSE: TMO）是一家全球科學儀器、試劑和耗材、軟件及服務的提供商，支持研究、臨牀和工業實驗室。該公司提供分析儀器和實驗室設備、生命科學試劑和試劑盒、專業診斷以及研究人員、臨牀醫生和製造商使用的廣泛耗材。其產品還包括實驗室信息管理和數據分析軟件，以及幫助客户高效運行復雜工作流程的服務解決方案，如儀器維護、驗證和物流。</p>
<p>賽默飛世爾通過多個業務領域運營，廣泛涵蓋生命科學解決方案、分析儀器、專業診斷、實驗室產品和生物製藥服務，包括為製藥和生物技術公司提供的合同開發和製造服務。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比賽默飛世爾更好</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “3 美元人工智能奇蹟股票” 即將爆發</li>
<li>有哪些費用可以從資本利得税中扣除？</li>
<li>你知道亞馬遜計劃在 1 月 1 日做什麼嗎？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
</ul>
<p><strong>想看看其他對 TMO 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com，獲取賽默飛世爾公司（NYSE:TMO - 免費報告）的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在賽默飛世爾嗎？</h2>
<p>在考慮賽默飛世爾之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而賽默飛世爾並不在名單上。</p>
<p>雖然賽默飛世爾目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

賽默飛世爾

<p>Norden Group LLC 在第三季度將其在賽默飛世爾的持股減少了 76.3%，目前持有 1,315 股，價值 63.8 萬美元。其他對沖基金也調整了其持股，分析師提高了價格目標和評級。內部交易方面，副總裁 Lisa P. Britt 和執行副總裁 Michael D. Shafer 進行了大量股票出售。該股票開盤價為 580.65 美元，市值為 2181.6 億美元</p>

<p>Norden Group LLC decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 76.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,315 shares of the medical research company's stock after selling 4,226 shares during the period. Norden Group LLC's holdings in Thermo Fisher Scientific were worth $638,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Norden Group LLC 在最近向證券交易委員會（SEC）提交的 13F 表格中表示，在第三季度將其在賽默飛世爾（Thermo Fisher Scientific Inc.，NYSE:TMO - 免費報告）的持股減少了 76.3%。該機構投資者在此期間出售了 4,226 股後，持有該醫療研究公司 1,315 股股票。Norden Group LLC 在賽默飛世爾的持股在最近一個季度末的價值為 638,000 美元。</p>
</div><ul>
<li>Sector Rotation: 2 Smart Money Moves for 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>行業輪動：2026 年的 2 個聰明資金動向</li>
</ul>
</div><p>Other hedge funds also recently modified their holdings of the company. Heathbridge Capital Management Ltd. acquired a new position in Thermo Fisher Scientific during the third quarter worth about $230,000. Triangle Securities Wealth Management boosted its position in shares of Thermo Fisher Scientific by 5.2% during the 3rd quarter. Triangle Securities Wealth Management now owns 2,805 shares of the medical research company's stock valued at $1,360,000 after purchasing an additional 139 shares in the last quarter. Founders Financial Securities LLC raised its holdings in shares of Thermo Fisher Scientific by 11.1% in the 3rd quarter. Founders Financial Securities LLC now owns 2,367 shares of the medical research company's stock worth $1,148,000 after purchasing an additional 237 shares in the last quarter. Cape ANN Savings Bank acquired a new stake in Thermo Fisher Scientific during the third quarter valued at approximately $210,000. Finally, Value Partners Investments Inc. grew its position in Thermo Fisher Scientific by 1.6% in the third quarter. Value Partners Investments Inc. now owns 10,440 shares of the medical research company's stock worth $5,061,000 after buying an additional 160 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他對沖基金最近也調整了對該公司的持股。Heathbridge Capital Management Ltd. 在第三季度新購入了約 230,000 美元的賽默飛世爾股份。Triangle Securities Wealth Management 在第三季度將其在賽默飛世爾的持股增加了 5.2%。Triangle Securities Wealth Management 目前持有 2,805 股該醫療研究公司的股票，價值 1,360,000 美元，此前在上個季度又購買了 139 股。Founders Financial Securities LLC 在第三季度將其在賽默飛世爾的持股增加了 11.1%。Founders Financial Securities LLC 目前持有 2,367 股該醫療研究公司的股票，價值 1,148,000 美元，此前在上個季度又購買了 237 股。Cape ANN Savings Bank 在第三季度新購入了約 210,000 美元的賽默飛世爾股份。最後，Value Partners Investments Inc. 在第三季度將其在賽默飛世爾的持股增加了 1.6%。Value Partners Investments Inc. 目前持有 10,440 股該醫療研究公司的股票，價值 5,061,000 美元，此前在上個季度又購買了 160 股。目前，89.23% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>Several equities research analysts have recently weighed in on the company. Citigroup raised Thermo Fisher Scientific from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and raised their price objective for the stock from $580.00 to $660.00 in a research note on Thursday, December 11th. KeyCorp raised Thermo Fisher Scientific from a &#34;sector weight&#34; rating to an &#34;overweight&#34; rating and set a $750.00 price target on the stock in a research note on Sunday, December 7th. Hsbc Global Res upgraded Thermo Fisher Scientific from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Monday, December 1st. UBS Group raised their target price on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a &#34;neutral&#34; rating in a report on Thursday, October 23rd. Finally, TD Cowen boosted their price target on shares of Thermo Fisher Scientific from $612.00 to $654.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, October 23rd. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $616.60.</p>
<div class="lb-trans"><p>幾位股票研究分析師最近對該公司發表了看法。花旗集團將賽默飛世爾的評級從 “中性” 上調至 “買入”，並在 12 月 11 日的研究報告中將其目標價從 580.00 美元上調至 660.00 美元。KeyCorp 將賽默飛世爾的評級從 “行業權重” 上調至 “超配”，並在 12 月 7 日的研究報告中設定了 750.00 美元的目標價。滙豐全球研究在 12 月 1 日的報告中將賽默飛世爾的評級從 “持有” 上調至 “強力買入”。瑞銀集團在 10 月 23 日的報告中將賽默飛世爾的目標價從 500.00 美元上調至 590.00 美元，並給予該股票 “中性” 評級。最後，TD Cowen 在 10 月 23 日的報告中將賽默飛世爾的目標價從 612.00 美元上調至 654.00 美元，並給予公司 “買入” 評級。一位分析師給予該股票 “強力買入” 評級，二十位給予 “買入” 評級，三位給予 “持有” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 616.60 美元。</p>
</div><ul>
<li>Institutions Love These 3 Companies, Should You As Well?</li>
</ul>
<div class="lb-trans"><ul>
<li>機構熱愛這 3 家公司，你也應該嗎？</li>
</ul>
</div><p><strong>Check Out Our Latest Report on Thermo Fisher Scientific</strong></p>
<div class="lb-trans"><p><strong>查看我們關於賽默飛世爾的最新報告</strong></p>
</div><h2>Insider Transactions at Thermo Fisher Scientific</h2>
<div class="lb-trans"><h2>賽默飛世爾的內部交易</h2>
</div><p>In related news, VP Lisa P. Britt sold 10,225 shares of the business's stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $571.62, for a total value of $5,844,814.50. Following the completion of the sale, the vice president owned 14,145 shares of the company's stock, valued at approximately $8,085,564.90. The trade was a 41.96% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael D. Shafer sold 10,725 shares of the firm's stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total transaction of $6,435,000.00. Following the transaction, the executive vice president directly owned 18,731 shares in the company, valued at approximately $11,238,600. The trade was a 36.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 149,271 shares of company stock valued at $86,507,282. Corporate insiders own 0.33% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，副總裁 Lisa P. Britt 於 11 月 7 日星期五出售了 10,225 股公司的股票，交易平均價格為 571.62 美元，總價值為 5,844,814.50 美元。出售完成後，該副總裁持有 14,145 股公司的股票，價值約為 8,085,564.90 美元。此次交易使其持股減少了 41.96%。該出售在 SEC 的備案中披露，您可以通過此鏈接訪問。此外，執行副總裁 Michael D. Shafer 於 11 月 25 日星期二出售了 10,725 股公司的股票，交易平均價格為 600.00 美元，總交易額為 6,435,000.00 美元。交易完成後，該執行副總裁直接持有 18,731 股公司的股票，價值約為 11,238,600 美元。此次交易使其持股減少了 36.41%。該出售的披露信息可在 SEC 的備案中找到。在過去的九十天裏，內部人士已出售 149,271 股公司股票，價值 86,507,282 美元。公司內部人士持有 0.33% 的公司股票。</p>
</div><h2>Thermo Fisher Scientific Trading Up 0.3%</h2>
<div class="lb-trans"><h2>賽默飛世爾股票上漲 0.3%</h2>
</div><ul>
<li>These 3 Stocks Are Using Buybacks to Signal Market Confidence</li>
</ul>
<div class="lb-trans"><ul>
<li>這 3 只股票正在利用回購來傳達市場信心</li>
</ul>
</div><p>NYSE:TMO opened at $580.65 on Friday. The stock has a market cap of $218.16 billion, a PE ratio of 33.54, a price-to-earnings-growth ratio of 4.11 and a beta of 0.90. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The stock's 50-day moving average is $573.94 and its two-hundred day moving average is $502.88.</p>
<div class="lb-trans"><p>NYSE:TMO 週五開盤價為 580.65 美元。該股票的市值為 2181.6 億美元，市盈率為 33.54，市盈增長比率為 4.11，貝塔係數為 0.90。賽默飛世爾的 52 周低點為 385.46 美元，52 周高點為 610.97 美元。該公司的債務與股本比率為 0.62，流動比率為 1.50，速動比率為 1.11。該股票的 50 日移動平均線為 573.94 美元，200 日移動平均線為 502.88 美元。</p>
</div><p>Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping the consensus estimate of $5.50 by $0.29. The business had revenue of $11.12 billion during the quarter, compared to analysts' expectations of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The firm's quarterly revenue was up 4.9% compared to the same quarter last year. During the same period last year, the company posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>賽默飛世爾（NYSE:TMO - 獲取免費報告）最近於 10 月 22 日星期三發佈了季度財報。該醫療研究公司報告該季度每股收益為 5.79 美元，超出市場共識預期的 5.50 美元，超出幅度為 0.29 美元。該公司在該季度的收入為 111.2 億美元，而分析師預期為 109 億美元。賽默飛世爾的淨利潤率為 15.02%，股本回報率為 16.97%。該公司的季度收入較去年同期增長了 4.9%。去年同期，該公司每股收益為 5.28 美元。賽默飛世爾已將其 2025 財年的指導目標設定為每股收益 22.600-22.860 美元。整體來看，股票研究分析師預測賽默飛世爾在當前財年將發佈每股收益 23.28 美元。</p>
</div><h2>Thermo Fisher Scientific Dividend Announcement</h2>
<div class="lb-trans"><h2>賽默飛世爾分紅公告</h2>
</div><p>The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.94%.</p>
<div class="lb-trans"><p>該公司最近還披露了季度股息，將於 1 月 15 日（星期四）支付。12 月 15 日（星期一）登記的投資者將獲得每股 0.43 美元的股息。這相當於每年 1.72 美元的股息和 0.3% 的股息收益率。除息日期為 12 月 15 日（星期一）。賽默飛世爾的股息支付比率（DPR）目前為 9.94%。</p>
</div><p>Thermo Fisher Scientific announced that its board has initiated a stock repurchase plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's management believes its shares are undervalued.</p>
<div class="lb-trans"><p>賽默飛世爾宣佈，其董事會於 11 月 6 日（星期四）啓動了一項股票回購計劃，允許公司回購 50 億美元的股份。該回購授權允許這家醫療研究公司通過公開市場購買最多 2.4% 的股份。股票回購計劃通常表明公司的管理層認為其股票被低估。</p>
</div><h2>Thermo Fisher Scientific Profile</h2>
<div class="lb-trans"><h2>賽默飛世爾簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.</p>
<div class="lb-trans"><p>賽默飛世爾（NYSE: TMO）是一家全球科學儀器、試劑和耗材、軟件及服務的提供商，支持研究、臨牀和工業實驗室。該公司提供分析儀器和實驗室設備、生命科學試劑和試劑盒、專業診斷以及研究人員、臨牀醫生和製造商使用的廣泛耗材。其產品還包括實驗室信息管理和數據分析軟件，以及幫助客户高效運行復雜工作流程的服務解決方案，如儀器維護、驗證和物流。</p>
</div><p>Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.</p>
<div class="lb-trans"><p>賽默飛世爾通過多個業務領域運營，廣泛涵蓋生命科學解決方案、分析儀器、專業診斷、實驗室產品和生物製藥服務，包括為製藥和生物技術公司提供的合同開發和製造服務。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Thermo Fisher Scientific</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Do you know what Amazon is planning for January 1?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比賽默飛世爾更好</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “3 美元人工智能奇蹟股票” 即將爆發</li>
<li>有哪些費用可以從資本利得税中扣除？</li>
<li>你知道亞馬遜計劃在 1 月 1 日做什麼嗎？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TMO?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 TMO 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com，獲取賽默飛世爾公司（NYSE:TMO - 免費報告）的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=TMO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Thermo Fisher Scientific Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在賽默飛世爾嗎？</h2>
</div><p>Before you consider Thermo Fisher Scientific, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮賽默飛世爾之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而賽默飛世爾並不在名單上。</p>
</div><p>While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然賽默飛世爾目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Norden Group LLC 減少了其在賽默飛世爾公司 $TMO 的持股